Literature DB >> 6652117

Internalization of Clostridium difficile cytotoxin into cultured human lung fibroblasts.

I Florin, M Thelestam.   

Abstract

In cultured human lung fibroblasts treated with Clostridium difficile cytotoxin, the latency before appearance of the cytopathogenic effect was dose-related with a minimum of 45 min. At 37 degrees C, the toxin was accessible on all cells to inactivation with trypsin or neutralization with antitoxin during the first tenth of the latency. At 0 degrees C, the toxin was accessible considerably longer. The cytopathogenic effect was reversibly prevented by the lysosomotropic agents chloroquine and ammonium chloride, which had to be added within one-fifth of the latency to protect all cells. In the presence of chloroquine, but not of ammonium chloride, the time period during which the toxin remained amenable to neutralization with antitoxin was prolonged. The protective effect of ammonium chloride was not influenced by dropping the extracellular pH to 4.5, but that of chloroquine was abolished. The expression of the intoxication was not affected by inhibitors of the DNA, RNA or protein synthesis. Inhibitors of the energy metabolism prevented the cytopathogenic effect when added before the last phase of the latency. The results suggest that expression of the cytopathogenic effect requires internalization of the toxin, and that metabolic energy but no macromolecular synthesis is needed for the action of the toxin after this internalization.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652117     DOI: 10.1016/0167-4889(83)90100-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  22 in total

1.  Cellular internalisation of bacterial toxins.

Authors:  M Thelestam
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

Review 2.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells.

Authors:  E Chaves-Olarte; M Weidmann; C Eichel-Streiber; M Thelestam
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

4.  TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing.

Authors:  Jordi M Lanis; Logan D Hightower; Aimee Shen; Jimmy D Ballard
Journal:  Mol Microbiol       Date:  2012-02-28       Impact factor: 3.501

5.  Clostridium difficile toxin B inhibits carbachol-induced force and myosin light chain phosphorylation in guinea-pig smooth muscle: role of Rho proteins.

Authors:  C Lucius; A Arner; A Steusloff; M Troschka; F Hofmann; K Aktories; G Pfitzer
Journal:  J Physiol       Date:  1998-01-01       Impact factor: 5.182

Review 6.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

7.  Interaction of Clostridium difficile toxin A with cultured cells: cytoskeletal changes and nuclear polarization.

Authors:  C Fiorentini; W Malorni; S Paradisi; M Giuliano; P Mastrantonio; G Donelli
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

8.  Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication.

Authors:  Elaine E Hamm; Daniel E Voth; Jimmy D Ballard
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

9.  Early events in the action of staphylococcal alpha-toxin on the plasma membrane of adrenocortical Y1 tumor cells.

Authors:  L Blomqvist; M Thelestam
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

10.  Factors influencing the phagocytosis of Clostridium difficile by human polymorphonuclear leukocytes.

Authors:  D C Dailey; A Kaiser; R H Schloemer
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.